

Human TIE2 Protein; hFc Tag

Product Information


Product Name	Human TIE2 Protein; hFc Tag
Storage temp	Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	GM-88809RP-100 / 100 μg GM-88809RP-1000 / 1 mg

Protein Information

Alternative Names	Tie-2, TEK, VMCM, VMCM1, CD202b, Angiopoietin-1 receptor
Source	Human TIE2 Protein; hFc Tag (GM-88809RP) is expressed from human 293 cells (HEK-293). It contains AA Ala 23 - Leu 748 (Accession # Q02763-1). This protein carries a His tag at the C-terminus.
Purity	> 95% as determined by SDS-PAGE
Endotoxin	< 1 EU/ μg , determined by LAL gel clotting assay
Predicted Mol Mass	107.0 kDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	TIE2 protein, full name Tyrosine Kinase with Immunoglobulin-like and Epidermal Growth Factor-like Domains 2, also known as TEK receptor tyrosine kinase, is an important cell membrane receptor protein and a member of the angiopoietin receptor family. TIE2 protein plays a crucial role in regulating angiogenesis, vascular remodeling, and vascular integrity in normal physiological conditions, particularly during embryonic development, wound healing, and tissue repair. Currently, several TIE2-targeted therapeutic strategies are under preclinical or clinical investigation, including monoclonal antibodies such as Rebastinib and Trebananib (which neutralizes Ang-1 and Ang-2), as well as small-molecule tyrosine kinase inhibitors targeting the TIE2 pathway. These agents aim to inhibit the activation of the TIE2 signaling pathway, thereby disrupting abnormal angiogenesis, reducing tumor vascular supply, and suppressing tumor growth and metastasis. In summary, TIE2 protein plays a critical role in tumor angiogenesis and the tumor microenvironment, and is of great significance for understanding the mechanisms of tumor vascularization, developing novel anti-angiogenic and immunomodulatory therapeutic strategies, and evaluating patient prognosis, particularly in the context of combination cancer therapy and vascular-targeted treatments.


Version:4.0

SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Human TIE2 Protein; hFc Tag (Catalog # GM-88809RP) was immobilized at 2 µg/ml (100 µL/well). Increasing concentrations of Anti-TIE2 hIgG1 Antibody (Tie2 2.38) (Catalog # GM-51860AB) were added.